Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Aug 22;105(6):1527–1538. doi: 10.3324/haematol.2019.217414

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2020 Ferrata Storti Foundation

Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.

PMC Copyright notice

Figure 4. — Effect of midostaurin on the viability of CD34⁺CD38⁻, CD34⁺CD38⁺ and CD19⁺ cells derived from healthy donors, and acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL) patients. Averaged dose response curves for disease categories are presented as mean±standard error of mean. (A) While midostaurin treatment had no effect on CD34⁺CD38⁻cells from healthy individuals, variable sensitivity was detected in AML samples. (B) CD34⁺CD38⁺ cells derived from FLT3-ITD-mutated AML samples displayed similar sensitivity (median IC₅₀, 554nM). (C) CD19⁺ cells derived from healthy donor or patient samples showed comparable sensitivity at a median IC₅₀ of 319 nM. Individual dose response curves are provided in Online Supplementary Figure S8C. (D) Scatter plot showing dose responses for midostaurin in CD19⁺ cells from a CLL patient. The percentage of CD19⁺ live cells present in midostaurin-treated wells compared to untreated cells is displayed numerically on the plot. Cellular proportions for these samples are provided in Online Supplementary Table S5. Related IC₅₀ values are provided in Online Supplementary Table S6.